Quick Answer
Definium Therapeutics, Inc. reported Net Income Loss of -$183.79 million for the year ending 2025.
- Definium Therapeutics, Inc. showed a decrease of -69.1% in Net Income Loss from 2024 to 2025.
- This data is from Definium Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Definium Therapeutics, Inc.'s Net Income Loss has declined by 441.6%.
- Historical annual values: Fiscal year 2025: -$183.79 million | Fiscal year 2024: -$108.68 million | Fiscal year 2023: -$95.73 million | Fiscal year 2022: -$56.80 million | Fiscal year 2021: -$93.04 million | Fiscal year 2020: -$33.94 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: